4503 — Astellas Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual income statement for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,296,163	1,518,619	1,603,672	1,912,323	2,139,245
Cost of Revenue
Gross Profit	1,043,154	1,230,266	1,311,187	1,563,117	1,730,819
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,135,393	1,390,597	1,578,407	1,873,800	1,756,612
Operating Profit	160,770	128,022	25,265	38,523	382,633
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	156,886	132,361	24,969	31,237	376,587
Provision for Income Taxes
Net Income After Taxes	124,086	98,714	17,045	50,747	291,574
Minority Interest
Net Income Before Extraordinary Items
Net Income	124,086	98,714	17,045	50,747	291,534
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	124,086	98,714	17,045	50,747	291,535
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	95.3	92.8	45.6	103	161
Dividends per Share